Description
A histamine H3 receptor antagonist (Kis = 1.17 and 7.08 nM for human and rat receptors, respectively); increases extracellular norepinephrine and acetylcholine levels in the frontal cortex of rats at 10 mg/kg; reduces the number of cataplectic attacks and time spent in cataplexy in familial narcoleptic Dobermans at 1.25-10 mg/kg; decreases the time spent in the open areas of the elevated zero maze in mice at 10 mg/kg, as well as increases locomotor activity in an open field test; inhibits LPS-induced increases in time spent immobile in the tail suspension test in mice.
Formal name: 4-[[3-[4-(1-piperidinyl)-1-butyn-1-yl]phenyl]methyl]-morpholine, dihydrochloride
Synonyms: RWJ 662733
Molecular weight: 385.4
CAS: 544707-20-2
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Behavioral Neuroscience|Anxiety||Research Area|Neuroscience|Behavioral Neuroscience|Depression||Research Area|Neuroscience|Behavioral Neuroscience|Sleep & Biological Rhythms
